ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based ...

We are thrilled to welcome Dennis and Cristina to ProQR at such an important time in our evolution,” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “Dennis brings deep expertise ...

线粒体作为细胞的“能量工厂”，其基因组突变与母系遗传病、衰老及多种疾病密切相关。在已报道的疾病相关碱基替换中，超过40%的替换为G-to-A/C-to-T突变，这些突变可以通过A-to-G碱基编辑恢复。但是目前可对线粒体基因组进行A-to-G碱基编辑 ...

Binding of miR-3036-5p to CYP18A1 can be prevented by an A-to-I RNA editing, thus elevating CYP18A1 expression, decreasing 20E titer, and finally regulating the wing dimorphism of offspring in aphid.

AIR-001 is designed to restore functional alpha-1 antitrypsin (M-AAT) protein production by precisely repairing the SERPINA1 mutation (PiZ) to address the underlying cause of both lung and liver ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

Background: Probiotics have been demonstrated to exert a potential clinical enhancing effect in cancer patients receiving immune checkpoint inhibitors (ICIs), while antibiotics exert a detrimental ...

ADAR1 converts adenosine to inosine in double-stranded RNA, a process essential for preventing unwarranted immune responses, yet the molecular basis of this editing had remained unclear.

ADAR1 converts adenosine to inosine in double-stranded RNA, a process essential for preventing unwarranted immune responses, yet the molecular basis of this editing had remained unclear.